Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
238lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
6 lessons
8mProtocolsIntermediate
CT-388 Dosing Guide: Weekly Dual GLP-1/GIP Up to 24 mg
CT-388 is Roche's weekly tirzepatide-class dual agonist with Phase 2 doses up to 24 mg. Here's the dosing vocabulary and the weight-loss signal searchers want.
8mResearchAdvanced
Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
8mResearchAdvanced
Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.
8mProtocolsIntermediate
Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity
Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.
7mProtocolsIntermediate
Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained
Mazdutide is a once-weekly glucagon/GLP-1 dual agonist with clear Phase 3 dose anchors at 4 mg and 6 mg. Here's the dosing and results map searchers want.
10mPeptidesIntermediate
Tirzepatide: The Dual Agonist Revolution in Weight Loss
Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.
Also available at /blog for legacy links.